Relapse of chilblain‐like lesions during the second wave of coronavirus disease 19

Recalcati, Sebastiano; Barbagallo, Tania; Tonolo, Silvia; Milani, Mario; Fantini, Fabrizio

doi:10.1111/jdv.17168

Cited by 11 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Europe has faced a second wave of the pandemic since October 2020. As we had observed in our area, a new outbreak of chilblains was also reported in Italy concomitantly with the second wave 5 . Recently, the first relapses in patients who experienced chilblains during the first wave were reported 5 .…”

Section: Relapse No Relapse or For Relapsedsupporting

confidence: 76%

“…As we had observed in our area, a new outbreak of chilblains was also reported in Italy concomitantly with the second wave. 5 Recently, the first relapses in patients who experienced chilblains during the first wave were reported. 5 The aim of this study was to explore, in our cohort of chilblain-like lesions, 4 the occurrence of relapses and exposure to COVID-19 in households during the second wave.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Relapse of chilblain‐like lesions during the second wave of the COVID‐19 pandemic: a cohort follow‐up

Hubiche¹,

Duff²,

Fontas

et al. 2021

Br J Dermatol

View full text Add to dashboard Cite

show abstract

Section: Relapse No Relapse or For Relapsedsupporting

confidence: 76%

mentioning

confidence: 99%

Relapse of chilblain‐like lesions during the second wave of the COVID‐19 pandemic: a cohort follow‐up

Hubiche¹,

Duff²,

Fontas

et al. 2021

Br J Dermatol

View full text Add to dashboard Cite

show abstract

“…That localized acral skin injury might be the result of robust immune‐mediated response triggered by SARS‐CoV‐2. CLL patients hence present with mild or no symptoms, negative RT‐PCR, and localized endothelial damage to the acral sites 4 . CLL patients are liable to relapse at new contact with SARS‐CoV‐2 4 .…”

Section: Figurementioning

confidence: 99%

“…CLL patients hence present with mild or no symptoms, negative RT‐PCR, and localized endothelial damage to the acral sites 4 . CLL patients are liable to relapse at new contact with SARS‐CoV‐2 4 . With deployment of inactivated SARS‐CoV‐2 vaccine, it is aimed to create an optimum immunological response by giving attenuated particles of the virus.…”

Section: Figurementioning

confidence: 99%

Acral chilblain‐like lesions following inactivated SARS‐CoV‐2 vaccination

et al. 2021

View full text Add to dashboard Cite

“…wave in patients who had comparable lesions in the same anatomic areas in the previous pandemic wave, together with the occurrence of new cases during the second wave of COVID-19, strongly suggests that chilblains are closely related to SARS-CoV-2 infection 23,[27][28][29]. Three recent cases of BNT162b2 mRNA COVID-19 vaccine (Pfizer)-induced chilblains further reinforce the hypothesis of their relationship with SARS-CoV-2 [30][31][32].…”

mentioning

confidence: 78%

A clinicopathological description of COVID‐19‐induced chilblains (COVID‐toes) correlated with a published literature review

et al. 2021

View full text Add to dashboard Cite

Background: The abundance of publications of COVID-19-induced chilblains has resulted in a confusing situation. Methods: This is a prospective single-institution study from 15 March to 13 May 2020. Thirty-two patients received PCR nasopharyngeal swabs. Of these, 28 patients had a thoracic CT-scan, 31 patients had blood and urine examinations, 24 patients had skin biopsies including immunohistochemical and direct immunofluorescence studies, and four patients had electron microscopy. Results: COVID-19-induced chilblains are clinically and histopathologically identical to chilblains from other causes. Although intravascular thrombi are sometimes observed, no patient had a systemic coagulopathy or severe clinical course. The exhaustive clinical, radiological, and laboratory work-up in this study ruled-out other primary and secondary causes. Electron microscopy revealed rare, probable viral particles whose core and spikes measured from 120 to 133 nm within endothelium and eccrine glands in two cases. Conclusion: This study provides further clinicopathologic evidence of COVID-19-related chilblains. Negative PCR and antibody tests do not rule-out infection. Chilblains represent a good prognosis, occurring later in the disease course. No systemic coagulopathy was identified in any patient. Patients presenting with acral lesions should be isolated, and chilblains should be distinguished from thrombotic lesions (livedo racemosa, retiform purpura, or ischemic acral necrosis).

show abstract

Relapse of chilblain‐like lesions during the second wave of coronavirus disease 19

Cited by 11 publications

References 10 publications

Relapse of chilblain‐like lesions during the second wave of the COVID‐19 pandemic: a cohort follow‐up

Relapse of chilblain‐like lesions during the second wave of the COVID‐19 pandemic: a cohort follow‐up

Acral chilblain‐like lesions following inactivated SARS‐CoV‐2 vaccination

A clinicopathological description of COVID‐19‐induced chilblains (COVID‐toes) correlated with a published literature review

Contact Info

Product

Resources

About